Ajinomoto, Astellas Pharma Jointly File Application Seeking Additional Approval for Combination Therapy of FASTIC/STARSIS Tablets, Fast-acting Postprandial Hypoglycemic Agent, with Biguanide.
The two companies expect approval for combination therapy of FASTCI/STARSIS with biguanide agents. Nateglinide, which is an amino acid derivative, is an oral hypoglycemic agent launched in August 1999.
Copyright [c] 2006 Japan Corporate News Network. All rights reserved.
|Printer friendly Cite/link Email Feedback|
|Publication:||JCNN News Summaries|
|Date:||Feb 1, 2006|
|Previous Article:||Chugai Pharmaceutical Renovates Its Website for Actemra, Drug for the Castleman's Disease.|
|Next Article:||Sysmex America, ACL Laboratories Collaborate in Hematology Analysis.|